NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 15 March 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Jane Adam (Chair - Topics 1, 3 & 4) Present for all items
2. Dr Brian Shine (Chair – Topic 2) Present for all items
3. Professor Abdallah Al-Mohammad Present for all items
4. Dr Peter Baker-Gulliver Items 4.1.3 to 7.1.3
5. Richard Ballerand Items 5 to 7.2.2
6. Dr Justin Daniels Present for all items
7. Ana Duarte Present for all items
8. Dr Rita Faria Items 1 to 7.1.3
9. Dr Michael Holmes Present for all items
10. Dr Bernard Khoo (TAC D Volunteer) Items 6 to 7.2.2
11. Dr Fiona MacPherson Smith Present for all items
12. Dr Malcolm Oswald (TAC D Volunteer) Present for all items
13. Hugo Pedder Present for all items
14. Dominic Pivonka Items 1 to 5.3.2 & 7 to 7.2.2
15. Alan Thomas Present for all items
16. Min Ven Teo Items 1 to 4.2.2
17. Dr Roger Whittaker Items 1 to 6.2.2

NICE staff present

Janet Robertson, Associate Director Items 1 to 4.2.2 & 6 to 7.2.2

Henry Edwards, Associate Director Items 5 to 5.3.2

Gavin Kenny, Project Manager Items 1 to 4.2.2

Jeremy Powell, Project Manager Items 5 to 5.3.2

Thomas Feist, Project Manager Items 6 to 7.2.2

Natalie Spray, Programme Manager, Planning and Operations Items 7 to 7.2.2

Eleanor Donegan, Heath Technology Assessment Adviser Items 1 to 4.2.2

Carl Prescott, Heath Technology Assessment Adviser Items 5 to 5.3.2

Mary Hughes, Heath Technology Assessment Adviser Items 6 to 6.3.2

Joanna Richardson, Heath Technology Assessment Adviser Items 7 to 7.2.2

Claire Hawksworth, Heath Technology Assessment Analyst Items 1 to 4.2.2

Catherine Spanswick, Heath Technology Assessment Analyst Items 5 to 5.3.2

Sana Khan, Heath Technology Assessment Analyst Items 6 to 6.3.2

Alexandra Sampson, Technology Assessment Analyst Items 6 to 6.3.2

Albany Meikle, Heath Technology Assessment Analyst Items 7 to 7.2.2

Adam Storrow, Business Analyst, RIA Items 1 to 5.3.2

David Tyldesley, Business Analyst, RIA Items 7 to 7.2.2

Korin Knight, Senior Medical Editor Items 1 to 4.2.2

Sarah Bromley, Senior Medical Editor Items 5 to 5.3.2

Hayley Garnett, Senior Medical Editor Items 6 to 7.2.2

Matthew Brown, Communications Lead, Media Relations Items 7 to 7.2.2

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment, Present for all items

Stephen Norton, Technical Analyst, Managed Access Items 1 to 4.2.2

Catrin Austin, Technical Analyst, Methods, and economics Items 5 to 5.3.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 6 to 6.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.2.2 & 6 to 6.2.2

Catherine Pank, Assistant Project Manager, COT Items 7 to 7.2.2

Lucinda Evans, Coordinator, MIP Items 1 to 4.1.2 & 6 to 6.1.3

Rosalee Mason, Coordinator, MIP Items 5 to 5.1.3 & 7 to 7.2.2

Gemma Smith, Coordinator, COT Present for all items

Rumana Zaman, Administrator, TA Items 5 to 5.3.2

Marcia Miller, Administrator, TA Items 6 to 6.2.2

External assessment group representatives present

Emanuela Castelnuovo, Warwick Evidence Items 1 to 4.1.3

Lena Al-Khudairy, Warwick Evidence Items 1 to 4.1.3

Aline Navega Biz, School of Health, and Related Research (ScHARR), Items 5 to 5.2.1 & 6 to 6.1.3

Paul Tappenden, School of Health, and Related Research (ScHARR), Items 5 to 5.2.1 & 6 to 6.1.3

Keith Cooper, Southampton Health Technology Assessment Centre (SHTAC) Items 7 to 7.1.3

Karen Pickett, Southampton Health Technology Assessment Centre (SHTAC) Items 7 to 7.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 6.2.2

Holly Heath, Policy Manager, patient expert, nominated by Breast Cancer Now, Items 1 to 4.1.3 & 5 to 5.1.3

Dr Alicia Okines, Consultant Medical Oncologist, clinical expert nominated by Royal College of Physicians, Items 1 to 4.1.3

Professor Peter Schmid, Lead at Centre of Experimental Cancer Medicine, clinical expert nominated by Gilead Sciences Ltd, Items 1 to 4.1.3

Nicola Tracey, Patient expert nominated by Breast Cancer Now, Items 1 to 4.1.3

Dr Catherine Harper-Wynne, Consultant Medical Oncologist, clinical expert, nominated by Royal College of Physicians, Items 5 to 5.1.3

Dr Alistair Ring, Consultant in Medical Oncology, clinical expert nominated by Novartis Items 5 to 5.1.3

Professor Gary McVeigh, Innovative Medicines Fund Clinical Lead, NHS England, Items 7 to 7.2.2

NHSE & NICE Observers present

Catherine White, recently appointed Appeal Panel Member, NICE, Items 1 to 4.2.2 & 6 to 7.2.2

Dr Sanjeev Patel, future Innovative Medicines Fund Clinical Lead, NHS England, Items 7 to 7.2.2

## Minutes

### Introduction to the meeting

* 1. The chair Dr Jane Adam welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. Committee members were reminded of the importance of responding to the DOI and attendance email in a timely fashion.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 15 February.

### Appraisal of sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after 2 or more therapies [ID3942]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Gilead Sciences Ltd
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated patient experts Holly Heath and Nicola Tracey declared indirect financial interests as in the last 12 months Breast Cancer Now has received funding from the manufacturer Gilead and possible comparator company Roche towards our living with secondary breast cancer support service. Breast Cancer Now also launched a campaign in summer 2021 aimed at Gilead providing early access to Trodelvy following licensing through Project Orbis. More information on this can be found here <https://breastcancernow.org/get-involved/campaign-us/time-trodelvy>. It was agreed that their declarations would not prevent them from providing expert advice to the committee.
* Nominated clinical expert Dr Alicia Okines declared direct financial interests as she has received Research funding from Pfizer and Roche, Conference support from AstraZeneca, Lilly, Leo Pharmaceuticals, Daiichi-Sankyo, Advisory Board fees from Roche, Seagen, Astra Zeneca and Daiichi-Sankyo and Speaker fees from Pfizer, Seagen, Lilly, Daiichi-Sankyo, and Gilead. She is also a principal investigator in the TROPICS-02 trial of Sacituzumab govitecan. It was agreed that her declarations would not prevent Dr Okines from providing expert advice to the committee.
* Nominated clinical expert Professor Peter Schmid declared financial and personal interests as he has received honorarium for advisory and research boards from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Gilead, Merck, MSD, Novartis, Pfizer, Puma, and Roche. His institution has received grants and funding from Astellas, AstraZeneca, Genentech, Novartis, Oncogenex, Roche, Medivation and his spouse is an employee of Roche. It was agreed that his declarations would not prevent Professor Schmid from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Ana Duarte, Dr Fiona Macpherson Smith, and Alan Thomas.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10829>

### Appraisal of alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer [ID3929]

* 1. Part 1 – Open session
     1. The chair Dr Brian Shine welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis Pharmaceuticals
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated patient expert Holly Heath declared indirect financial interests as in the last 12 months Breast Cancer Now has received funding from the manufacturer Novartis and possible comparator companies Lilly UK and Pfizer either towards our living with secondary breast cancer support service or our service pledge work with hospitals. It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
* Nominated clinical expert Dr Catherine Harper-Wynne declared financial interests as she has acted as an advisor on advisory boards for Novartis for other agents and received honoraria as chair of an educational meeting conducted by Novartis for this agent. It was agreed her declarations would not prevent Dr Harper-Wynne from providing expert advice to the committee.
* Nominated clinical expert Dr Alistair Ring declared financial interests as he has received fees for consultancy from Novartis and within the last 12 months and ongoing, he has conducted consultancy for companies with agents used to treat advanced and early breast cancer: Roche, Lilly, Pfizer, AstraZeneca, Daiichi Sankyo, MSD, and Gilead. It was agreed his declarations would not prevent Dr Ring from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Peter Baker and Dr Michael Holmes
  1. Part 2a – Closed session (clinical and patient experts, company representatives and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10825>

### Appraisal of ibrutinib for treating waldenstrom’s macroglobulinaemia - CDF Review of TA491 [ID3778]

* 1. Part 1 – Open session
     1. The chair Dr Jane Adam welcomed the NHS England expert, external assessment group representatives, members of the public and company representatives from Janssen.
     2. The chair asked all committee members, NHSE expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dominic Pivonka declared financial interests as his employer (AbbVie) acquired the company which developed ibrutinib in 2015 and markets ibrutinib in the United States. As a direct conflict Dominic did not participate in discussions on this appraisal.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10827>

### Appraisal of semaglutide for managing overweight and obesity [ID3850]

* 1. Part 1 – Open session
     1. The chair Dr Jane Adam welcomed the NHSE experts, external assessment group representatives, members of the public and company representatives from Novo Nordisk Ltd
     2. The chair asked all committee members and NHSE experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Michael Holmes declared non-personal financial interest as he is collaborating with Novo Nordisk in an academic collaboration at the University of Oxford. This is in relation to a proteomics dataset which will be used to explore potential therapeutic targets. It was agreed that his declaration would not prevent Dr Holmes from participating in discussions on this appraisal.
* Committee member Dr Bernard Khoo declared non-financial professional interests as he has prescribed semaglutide for diabetes and obesity both in NHS practice and privately, he is also married to a metabolic medicine physician who is involved in a Tier 3 NHS obesity clinic and will be prescribing semaglutide according to guidance from NICE. It was agreed that his declarations would not prevent Dr Khoo from participating in discussions on this appraisal.
* No further interests were declared for this item.
  + 1. The Chair led a discussion of the evidence presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10765>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 12 April 2022 and will start promptly at 09.30.